1.        Steiner G, Skriner K, Hassfeld W, Smolen JS. Clinical and immunological aspects of autoantibodies to RA33/hnRNP-A/B proteins--a link between RA, SLE and MCTD. Mol Biol Rep 1996; 23(3-4):167-171.

0.565

2.        Vitali C, Bombardieri S, Moutsopoulos HM, Coll J, Gerli R, Hatron PY, Kater L, Konttinen YT, Manthorpe R, Meyer O, Mosca M, Ostuni P, Pellerito RA, Pennec Y, Porter SR, Richards A, Sauvezie B, Schiodt M, Sciuto M, Shoenfeld Y, Skopouli FN, Smolen JS, Soromenho F, Tishler M, Wattiaux MJ. Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis 1996; 55(2):116-121.

3.827

3.        Leeb BF, Machold KP, Smolen JS. Diagnosis and therapy of chronic polyarthritis. Radiologe 1996; 36(8):657-662.

0.626

4.        Steiner G, Skriner K, Smolen JS. Autoantibodies to the A/B proteins of the heterogeneous nuclear ribonucleoprotein complex: novel tools for the diagnosis of rheumatic diseases. Int Arch Allergy Imm 1996; 111(4):314-319.

2.000

5.        Valenta R, Maurer D, Steiner R, Seiberler S, Sperr WR, Valent P, Spitzauer S, Kapiotis S, Smolen J, Stingl G. Immunoglobulin E response to human proteins in atopic patients. J Invest Dermatol 1996; 107(2):203-208.

4.194

6.        Partsch G, Steiner G, Leeb BF, Dunky A , Bröll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24(3):518-523.

2.674

7.        Smolen JS, Steiner G, Tan EM. Standards of care: the value and importance of standardization. Arthritis Rheum 1997; 40(3):410-412.

7.190

8.        Smolen JS, Butcher B, Fritzler MJ, Gordon T, Hardin J, Kalden JR, Lahita R, Maini RN, Reeves W, Reichlin M, Rothfield N, Takasaki Y, van Venrooij WJ, Tan EM. Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. Arthritis Rheum 1997; 40(3):413-418.

7.190

9.        van de Putte LB, Tyndall A, van den Hoogen FH, Smolen JS. Hematopoietic stem cell transplants for autoimmune disease: role of EULAR. European League Against Rheumatism. J Rheumatol Suppl 1997; 48:98-99.

2.674

10.    Skriner K, Sommergruber WH, Tremmel V, Fischer I, Barta A, Smolen JS, Steiner G. Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease. J Clin Invest 1997; 100(1):127-135.

14.307

11.    Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA,  Kalden JR, Lahita RG, Maini RN, McDougal JS, Rothfield NF, Smeenk RJ, Takasaki Y, Wiik A, Wilson MR, Koziol JA. Range of antinuclear antibodies in healthy individuals. Arthritis Rheum 1997; 40(9):1601-1611.

7.190

12.    Graninger WB, Smolen JS. Should the clinician have interest in the deregulation of apoptosis in autoimmunity? Br J Rheumatol 1997; 36(12):1244-1246.

3.760

13.    Aringer M, Graninger WB, Smolen JS, Kiener HP, Steiner CW, Trautinger F, Knobler R. Photopheresis treatment enhances CD95 (fas) expression in circulating lymphocytes of patients with systemic sclerosis and induces apoptosis. Br J Rheumatol 1997; 36(12):1276-1282.

3.760

14.    Kainberger F, Machold K, Liskutin J, Kritz H, Smolen J. Ultrasonography of the locomotor system: recent developments and trends. Rheumatology in Europe 1997; 26:86-88.

3.760

15.    Kiener HP, Baghestanian M, Dominkus M, Walchshofer S, Ghannadan M, Willheim M, Sillaber C, Graninger WB, Smolen JS, Valent P. Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum  1998; 41(2):233-245.

7.190

16.    Aringer M, Smolen JS, Graninger WB. Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis Rheum 1998; 41(3):414-420.

7.190

17.    Erlacher L, Wyatt J, Pflugbeil S, Köller M, Ullrich R, Vogelsang H, Smolen JS, Graninger W. Sucrose permeability as a marker for NSAID-induced gastroduodenal injury. Clin Exp Rheumatol 1998; 16(1):69-71.

1.919

18.    Smolen JS, Steiner G. Mixed connective tissue disease: to be or not to be? Arthritis Rheum 1998; 41(5):768-777.

7.190

19.    Smolen JS, Steiner G. Are autoantibodies active players or epiphenomena? Curr Opin Rheumatol 1998; 10(3):201-206.

3.150

20.    Richter Cohen M, Steiner G, Smolen JS, Isenberg DA. Erosive arthritis in systemic lupus erythematosus: analysis of a distinct clinical and serological subset. Br J Rheumatol 1998; 37(4):421-424.

3.760

21.    Machold KP, Eberl G, Leeb BF, Nell V, Windisch B, Smolen JS. Early arthritis therapy: rationale and current approach. J Rheumatol Suppl 1998; 53:13-19.

2.674

22.    Schett G, Steiner G, Smolen JS. Nuclear antigen histone H1 is primarily involved in lupus erythematosus cell formation . Arthritis Rheum 1998; 41(8):1446-1455.

23.    7.190

24.    Pietschmann P, Stohlawetz P, Brosch S, Steiner G, Smolen JS, Peterlik M. The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells. Calcified Tissue Int 1998; 63(4):325-330.

2,198

25.    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41(9):1552-1563.

7.190

26.    Scheinecker C, Machold KP, Majdic O, Höcker P, Knapp W, Smolen JS. Initiation of the autologous mixed lymphocyte reaction requires the expression of costimulatory molecules B7-1 and B7-2 on human peripheral blood dendritic cells. J Immunol 1998; 161(8):3966-3973.

6.702

27.    Zimmermann C, Steiner G, Skriner K, Hassfeld W, Petera P, Smolen JS. The concurrence of rheumatoid arthritis and limited systemic sclerosis: clinical and serologic characteristics of an overlap syndrome. Arthritis Rheum 1998; 41(11):1938-1945.

7.190

28.    Aringer M, Kiener HP, Koeller MD, Artemiou O, Zuckermann A, Wieselthaler G, Klepetko W, Seidl G, Kainberger F, Bernecker P, Smolen JS, Pietschmann P. High turnover bone disease following lung transplantation. Bone 1998; 23(5):485-488.

0.869

29.    Smolen JS, Zimmermann C, Steiner G, Skriner K, Hassfeld W, Petera P. Limited systemic sclerosis and rheumatoid arthritis - characteristics of a new overlap disorder. Chromosome Research 1998; 6:592-593.

2.346

30.    Stohlawetz P, Hahn P, Köller M, Hauer J, Resch H, Smolen J, Pietschmann P. Immunophenotypic characteristics of monocytes in elderly subjects. Scand J Immunol 1998; 48(3):324-326.

1.942

31.    Wiesinger GF, Quittan M, Aringer M, Seeber A, Volc-Platzer B, Smolen J, Graninger W. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme. Br J Rheumatol 1998; 37(2):196-200.

32.    3.760

32.    Galeazzi M, Morozzi G, Sebastiani GD, Bellisai F, Marcolongo R, Cervera R, Ramòn Garrido E, Fernandez-Nebro A, Houssiau F, Jedryka-Goral A, Mathieu A, Papasteriades C, Piette JC, Scorza R, Smolen J. Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLE. Clin Exp Rheumatol 1998; 16(5):541-546.

1.919

33.    Galeazzi M, Bellisai F, Sebastiani GD, Morozzi G, Marcolongo R, Cervera R, Garrido ED, Nebro AF, Houssiau F, Goral AJ, Mathieu A, Papasteriades C, Piette JC, Scorza R, Smolen J. Association of 16/6 and SA1 anti-DANN idiotypes with antibodies and clinical manifestations in a large cohort of SLE patients. Clin Exp Rheumatol 1998; 17:717-721.

1.919

34.    Schett G, Redlich K, Xu Q, Bizan P, Gröger M, Tohidast-Akrad M, Kiener H, Smolen J, Steiner G. Enhanced expression of heat shock protein 70 (hsp70) and heat shock factor 1 (HSF1) activation in rheumatoid arthritis synovial tissue. Differential regulation of hsp70 expression and hsf1 activation in synovial fibroblasts by proinflammatory cytokines, shear stress, and antiinflammatory drugs. J Clin Invest 1998; 102(2):302-311.

14.307

35.    Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group . Lancet 1999; 353(9149):259-266.

18.316

36.    Smolen JS, Strand V, Cardiel M, Edworthy S, Furst D, Gladman D, Gordon C, Isenberg DA,  Klippel JH, Petri M, Simon L, Tugwell P, Wolfe F. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol 1999; 26(2):504-507.

2.674

37.    Tan EM, Smolen JS, McDougal JS, Butcher BT, Conn D, Dawkins R, Fritzler MJ, Gordon T,  Hardin JA, Kalden JR, Lahita RG, Maini RN, Rothfield NF, Smeenk R, Takasaki Y, van Venrooij WJ, Wiik A, Wilson M, Koziol JA. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum 1999; 42(3):455-464.

7.190

38.    Smolen JS. To the Christian-Georg-Schmorl-memorial lecture: 50 years of lupus erythemotosus cells. Z Rheumatol 1999; 58(1):2-4.

0.531

39.    Steiner G, Tohidast-Akrad M, Witzmann G, Vesely M, Studnicka-Benke A, Gal A, Kunaver M, Zenz P, Smolen JS. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 1999; 38(3):202-213.

3.760

40.    Hueber W, Hassfeld W, Smolen JS, Steiner G. Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology (Oxford) 1999; 38(2):155-159.

3.760

41.    Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, Breedveld FC, Smolen JS, Eberl G, deWoody K, Feldmann M, Maini RN. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163(3):1521-1528.

6.702

42.    Swaak AJG, van den Brink HG, Smeenk RJT, Manger K, Kalden JR, Tosi S, Marchesoni A, Domljan Z, Rozman B, Logar D, Pokorny G, Kovacs L, Kovacs A, Vlachoyiannopoulos PG, Moutsopoulos HM, Chwalinska-Sadowska H, Dratwianka B, Kiss E, Cikes N, Branimir A, Schneider M, Fischer R, Bombardieri S, Mosca M, Graninger W, Smolen JS. Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology 1999; 38:953-958.

3.760

43.    Furst DE, Breedveld FC, Burmester GR, Crofford L, Emery P, Feldman M, Kalden JR, Kavanaugh A, Keystone E, Lipsky PE, Maini RN, Moreland L, Smolen JS, Van De PL, Vischer T, Weinblatt M, Weissman M. Access to disease modifying treatments for rheumatoid arthritis patients. Ann Rheum Dis 1999; 58 Suppl 1:I129-I130.

3.827

44.    Furst DE, Keystone E, Maini RN, Smolen JS. Recapitulation of the round-table discussion - assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis. Rheumatology 1999; 38(Suppl 2):50-53.

3.760

45.    Smolen JS. Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis. Scand J Rheumatol Suppl 1999; 112:15-21.

1.821

46.    Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999; 26(2):490-497.

2.674

47.    Smolen JS, Steiner G. Reply. Arthritis Rheum 1999; 42:193-196.

7.190

48.    Emery P, Smolen J. Issues in rheumatoid arthritis. Lancet 1999; 353(9159):1186-1186.

18.316

49.    Smolen JS, Scott DL, Kalden JR, Löw-Friedrich I, Oed C. Leflunomide for active rheumatoid arthritis. Lancet 1999; 353:1883-1884.

18.316

50.    Brooks P, Emery P, Evans JF, Fenner H, Hawkey CJ, Patrone C, Smolen J, Breedveld F, Day R, Dougados M, Ehrlich EW, Gijon Banos J, Kvien TK, van Rijswijk MH, Warner T, Zeidler H. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology (Oxford) 1999; 38:779-788.

3.760

51.    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Hamman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354:1932-1939.

18.316

52.    Sebastiani GD, Galeazzi M, Tincani A, Piette JC, Font J, Allegri F, Mathieu A, Smolen J, De Ramon GE, Fernandez-Nebro A, Jedryka-Goral A, Papasteriades C, Morozzi G, Bellisai F, De Pita O, Marcolongo R. Anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations. European Concerted Action on the Immunogenetics of SLE. Scand J Rheumatol 1999; 28(6):344-351.

1.821

53.    Köller M, Aringer M, Kiener H, Erlacher L, Machold K, Eberl G, Studnicka-Benke A, Graninger W, Smolen J. Expression of adhesion molecules on synovial fluid and peripheral blood monocytes in patients with inflammatory joint disease and osteoarthritis. Ann Rheum Dis  1999; 58(11):709-712.

3.827

54.    Schett G, Steiner CW, Gröger M, Winkler S, Graninger W, Smolen J , Xu Q, Steiner G. Activation of Fas inhibits heat-induced activation of HSF1 and up-regulation of hsp70. FASEB J 1999; 13(8):833-842.

7.172

55.    Redlich K, Ziegler S, Kiener HP, Spitzauer S, Stohlawetz P, Bernecker P, Kainberger F, Grampp S, Kudlacek S, Woloszczuk W, Smolen JS, Pietschmann P. Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. Ann Rheum Dis 2000; 59(4):308-310.

3.827

56.    Eberl G, Studnicka-Benke A, Hitzelhammer H, Gschnait F, Smolen JS. Development of a disease activity index for the assessment of reactive arthritis (DAREA). Rheumatology (Oxford) 2000; 39(2):148-155.

3.760

57.    Hueber W, Hassfeld W, Smolen JS, Steiner G. Reply. Rheumatology (Oxford) 2000; 39(2):218.

3.760

58.    Aringer M, Vierhapper H, Graninger MT, Bernecker P, Smolen JS, Pietschmann P. Successful treatment of high turnover osteoporosis in a patient with adrenocortical insufficiency. Wien Klin Wochenschr 2000; 112(7):334-337.

0.774

59.    Isenberg DA, Smolen JS. European perspective of clinical trials in systemic lupus erythematosus. Lupus 2000; 9(4):233-235.

1.808

60.    Smolen JS, Breedveld FC, Burmester GR, Combe B, Emery P, Kalden JR, Klareskog L, Maini RN, Numo R, van de Putte LB, van Riel PL, Rodriguez-Valverde V. Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann Rheum Dis 2000; 59(7):504-505.

3.827

61.    Smolen JS, Graninger WB, Emery P. Leflunomide, a new disease-modifying anti-rheumatic drug and the never ending rheumatoid arthritis story. Rheumatology (Oxford) 2000; 39(7):689-692.

3.760

62.    Dumortier H, Monneaux F, Jahn-Schmid B, Briand JP, Skriner K, Cohen PL , Smolen JS, Steiner G, Muller S. B and T cell responses to the spliceosomal heterogeneous nuclear ribonucleoproteins A2 and B1 in normal and lupus mice. J Immunol 2000; 165(4):2297-2305.

6.702

63.    Furst DE, Breedveld FC, Burmester GR, Crofford JJ, Emery P, Feldmann M , Kalden JR, Kavanaugh AF, Keystone EC, Klareskog LG, Lipsky PE, Maini RN, Russell AS, Scott DL, Smolen JS, van de Putte LB, Visher TL, Weisman MH. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000). Ann Rheum Dis 2000; 59 Suppl 1:I1-I2.

3.827

64.    Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen JS, Steiner G, Rosen A, Zhang C, Menard HA, Zhou ZJ, Palosuo T, van Venrooij WJ, Wilder RL, Klippel JH, Schumacher HR, Jr., El Gabalawy HS. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000; 2(3):236-243.

5.036

65.    Kiener HP, Hofbauer R, Tohidast-Akrad M, Walchshofer S, Redlich K, Bitzan P, Kapiotis S, Steiner G, Smolen JS, Valent P. Tumor necrosis factor alpha promotes the expression of stem cell factor in synovial fibroblasts and their capacity to induce mast cell chemotaxis. Arthritis Rheum 2000; 43(1):164-174.

7.190

66.    Schett G, Rubin RL, Steiner G, Hiesberger H, Muller S, Smolen J. The lupus erythematosus cell phenomenon: comparative analysis of antichromatin antibody specificity in lupus erythematosus cell-positive and -negative sera. Arthritis Rheum 2000; 43(2):420-428.

7.190

67.    Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P , Zenz P, Redlich K, Xu Q, Steiner G. Activation, differential localization, and regulation of the stress- activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000; 43(11):2501-2512.

7.190

68.    Schett G, Steiner CW, Winkler S, Graninger W, Smolen J, Xu Q, Steiner G. Die gegenseitige Beeinflussung von Fas-Aktivierung und Stressproteinantwort entscheidet über Apoptose oder Restistenzentwicklung von Zellen. Acta Med Austriaca 2000; 27(3):94-98.

0,268

69.    Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis. New Engl J Med 2000; 343(22):1594-1602.

34.833

70.    Galeazzi M, Sebastiani GD, Tincani A, Piette JC, Allegri F, Morozzi G, Bellisai F, Scorza R, Ferrara GB, Carcassi C, Font J, Passiu G, Smolen J, Papasteriades C, Houssiau F, Nebro AF, Ramon Garrido ED, Jedryka-Goral A, Marcolongo R. HLA class II alleles associations of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus 2000; 9(1):47-55.

1.808

71.    Sperr WR, Natter S, Baghestanian M, Smolen J, Wolff K, Binder BR, Muller MR, Lechner K, Valenta R, Valent P. Autoantibody reactivity in a case of Schnitzler's syndrome: evidence for a Th1-like response and detection of IgG2 anti-FcepsilonRIalpha antibodies. Int Arch Allergy Imm 2000; 122(4):279-286.

2.000

72.    Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Lupus 2000; 9(5):322-327.

1.808

73.    Galeazzi M, Annunziata P, Sebastiani GD, Bellisai F, Campanella V, Ferrara GB, Font J, Houssiau F, Passiu G, De Ramon GE, Fernandez-Nebro A, Bracci L, Scorza R, Puddu P, Jedryka-Goral A, Smolen J, Tincani A, Carcassi C, Morozzi G , Marcolongo R. Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus: clinical, serological, and HLA class II gene associations. European Concerted Action on the Immunogenetics of SLE. J Rheumatol 2000; 27(1):135-141.

2.674

74.    Stacher G, Merio R, Budka C, Schneider C, Smolen J, Tappeiner G. Cardiovascular autonomic function, autoantibodies, and esophageal motor activity in patients with systemic sclerosis and mixed connective tissue disease. J Rheumatol 2000; 27(3):692-697.

2.674

75.    Lipsky PE, Abramson SB, Breedveld FC, Brook P, Burmester R, Buttgereit F, Cannon GW, Catella-Lawson F, Crofford LJ, Doherty M, Dougados M, DuBois RN, Froelich J, Garcia Rodriguez LA, Gibofsky A, Hernandez-Diaz S, Hochberg MC, Krause A,  Liang MH, Machold K, Peloso PM, Raisz LG, Schayes B, Scheiman JM, Simon LS, Smolen J. Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice. J Rheumatol 2000; 27( 6):1338-1340.

2.674

76.    Stummvoll GH, Aringer M, Smolen JS, Koller M, Kiener HP, Steiner CW , Bohle B, Knobler R, Graninger WB. Derangement of apoptosis-related lymphocyte homeostasis in systemic sclerosis. Rheumatology (Oxford) 2000; 39(12):1341-1350.

3.760

77.    Graninger WB, Steiner CW, Graninger MT, Aringer M, Smolen JS. Cytokine regulation of apoptosis and Bcl-2 expression in lymphocytes of patients with systemic lupus erythematosus. Cell Death Differ 2000; 7(10):966-972.

7.008

78.    Czerny C, Grampp S, Henk CB, Neuhold A , Stiskal M, Smolen J. Rheumatoid arthritis of the craniocervical region: assessment and characterization of inflammatory soft tissue proliferations with unenhanced and contrast-enhanced CT. Eur Radiol 2000; 10(9):1416-1422.

1.969

79.    Swaak AJ, van de Brink H, Smeenk RJ, Manger K, Kalden JR, Tosi S, Marchesoni A, Domljan Z, Rozman B, Logar D, Pokorny G, Kovacs L, Kovacs A, Vlachoyiannopoulos PG, Moutsopoulos HM, Chwalinska-Sadowska H, Dratwianka B, Kiss E, Cikes N, Anic B, Schneider M, Fischer R, Bombardieri S, Mosca M, Graninger W, Smolen JS. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford) 2001; 40(1):89-94.

3.760

80.    Grisar J, Hahn P, Brosch S, Peterlik M , Smolen JS, Pietschmann P. Phenotypic characteristics of human monocytes undergoing transendothelial migration. Arthritis Res 2001; 3(2):127-132.

5.036

81.    Redlich K, Kiener HP, Schett G, Tohidast-Akrad M, Selzer E, Radda I, Stummvoll GH, Steiner CW Groger M, Bitzan P, Zenz P, Smolen JS, Steiner G. Overexpression of transcription factor Ets-1 in rheumatoid arthritis synovial membrane: regulation of expression and activation by interleukin-1 and tumor necrosis factor alpha. Arthritis Rheum 2001; 44(2):266-274.

7.190

82.    Swaak AJ, van den Brink HG, Smeenk RJ, Manger K, Kalden JR, Tosi S, Domljan Z, Rozman B, Logar D, Pokorny G, Kovacs L, Kovacs A, Vlachoyiannopoulos PG, Moutsopoulos HM, Chwalinska-Sadowska H, Kiss E, Cikes N, Anic B, Schneider M, Fischer R, Bombardieri S, Mosca M, Graninger W, Smolen JS. Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation. Lupus 2001; 10(1):51-58.

1.808

83.    Stummvoll GH, Aringer M, Machold KP, Smolen JS, Raderer M. Cancer polyarthritis resembling rheumatoid arthritis as a first sign of hidden neoplasms. Report of two cases and review of the literature. Scand J Rheumatol 2001; 30(1):40-44.

1.821

84.    Graninger WB, Smolen JS. One-year inhibition of tumor necrosis factor-alpha: a major success or a larger puzzle? Curr Opin Rheumatol 2001; 13(3):209-213.

3.150

85.    Machold KP, Smolen JS. Stem cell transplantation: limits and hopes. Ann Rheum Dis 2001; 60(6):548-549.

3.827

86.    Larsen A, Kvien TK, Schattenkirchner M, Rau R, Scott DL, Smolen JS, Rozman B, Westhovens R, Tikly M, Oed C, Rosenburg R. Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scand J Rheumatol 2001; 30(3):135-142.

1.821

87.    Aringer M, Stummvoll GH, Steiner G, Koller M, Steiner CW, Hofler E, Hiesberger H, Smolen JS, Graninger WB. Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology (Oxford) 2001; 40(8):876-881.

3.760

88.    Kalden JR, Scott DL, Smolen JS, Schattenkirchner M, Rozman B, Williams BD, Kvien TK, Jones P, Williams RB, Oed C, Rosenburg R. Improved functional ability in patients with rheumatoid arthritis-- longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group. J Rheumatol 2001; 28(9):1983-1991.

2.674

89.    Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK, Schattenkirchner M, Nash P, Oed C, Loew-Friedrich I. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60(10):913-923.

3.827

90.    Smolen JS, Steiner G. Rheumatoid arthritis is more than cytokines: autoimmunity and rheumatoid arthritis. Arthritis Rheum 2001; 44(10):2218-2220.

7.190

91.    Furst DE, Keystone EC, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, Burmester GR, Crofford LJ, Kavanaugh A. Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases. Ann Rheum Dis 2001; 60(Suppl. III):iii2-iii5.

3.827

92.    Park JW, Smolen J. Monoclonal antibody therapy. Adv Protein Chem 2001; 56:369-421.

4.933

93.    Schett G, Tohidast-Akrad M, Steiner G, Smolen J. The stressed synovium. Arthritis Res 2001; 3(2):80-86.

5.036

94.    Cervera R, Khamashta MA, Font J, Hughes GR. European Working Party on Systemic Lupus Erythematosus: a 10 year report. Lupus 2001; 10(12):892-894.

1.808

95.    Wells G, Anderson J, Beaton D, Bellamy N, Boers M, Bombardier C, Breedveld F, Carr A, Cranney A, Dougados M, Felson D, Kirwan J, Schiff M, Shea B, Simon L, Smolen J, Strand V, Tugwell P, van Riel P, Welch VA. Minimal clinically important difference module: summary, recommendations, and research agenda. J Rheumatol 2001; 28(2):452-454.

2.674

96.    Schett G, Firbas U, Fureder W, Hiesberger H, Winkler S, Wachauer D, Koller M, Kapiotis S,  Smolen J. Decreased serum erythropoietin and its relation to anti-erythropoietin antibodies in anaemia of systemic lupus erythematosus. Rheumatology (Oxford) 2001; 40(4):424-431.

3.760

97.    Scheinecker C, Zwölfer B, Köller M, Männer G, Smolen JS. Alterations of dendritic cells in systemic lupus erythematosus: phenotypic and functional deficiencies. Arthritis Rheum 2001; 44(4):856-865.

7.190

98.    Aringer M, Steiner G, Graninger W, Smolen J. Role of tumor necrosis factor alpha and potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus: comment on the editorial by Pisetsky. Arthritis Rheum 2001; 44(7):1721-1722.

7.190

99.    Schett G, Hayer S, Tohidast-Akrad M, Schmid BJ, Lang S, Turk B, Kainberger F, Haralambous S, Kollias G, Newby AC, Xu Q, Steiner G, Smolen J. Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice. Arthritis Rheum 2001; 44(12):2888-2898.

7.190

100. Aletaha D, Smolen JS. Advances in anti-inflammatory therapy. Acta Med Austriaca 2002; 29(1):1-6.

0.268

101. Stamm TA, Machold KP, Smolen JS. Functional and health status assessment in patients with rheumatoid arthritis. Acta Med Austriaca 2002; 29(1):30-32.

0.268

102. Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast-Akrad M, Lang S, Turk B, Pietschmann P, Woloszczuk W, Haralambous S, Kollias G, Steiner G, Smolen JS, Schett G. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002; 46(3):785-792.

7.190

103. Huizinga TW, Machold KP, Breedveld FC, Lipsky PE, Smolen JS. Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis. Arthritis Rheum 2002; 46(5):1155-1159.

7.190

104. Brunner M, Greinix HT, Redlich K, Knobl P, Smolen J, Leitner G, Derfler K, Graninger W, Kalhs P, Machold K. Autologous blood stem cell transplantation in refractory systemic lupus erythematosus with severe pulmonary impairment: A case report. Arthritis Rheum 2002; 46(6):1580-1584.

7.190

105. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002; 61(4):290-297.

3.827

106. Tzioufas AG, Wassmuth R, Dafni UG, Guialis A, Haga HJ, Isenberg DA, Jonsson R, Kalden JR, Kiener H, Sakarellos C, Smolen JS, Sutcliffe N, Vitali C, Yiannaki E, Moutsopoulos HM. Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjogren's syndrome (pSS): a European multicentre study. Ann Rheum Dis 2002; 61(5):398-404.

3.827

107. Schett G, Winkler S, Hollenstein U, Amann G, Willheim M, Prokop M, Klepetko W, Becherer A, Smolen J, Graninger W. Obstruction of the pulmonary artery by granulomatous vasculitis: a clinical, morphological, and immunological analysis. Ann Rheum Dis 2002; 61(5):463-467.

3.827

108. Aletaha D, Eberl G, Nell VP, Machold KP, Smolen JS. Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years . Ann Rheum Dis 2002; 61(7):630-634.

3.827

109. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Antoni CE, Bijlsma JW , Burmester GR, Cronstein B, Keystone EC, Kavanaugh A, Klareskog L. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases. Ann Rheum Dis 2002; 61 Suppl 2:II2-II7.

3.827

110. Stamm TA, Machold KP, Smolen JS, Fischer S, Redlich K, Graninger W, Ebner W, Erlacher L.  Joint protection and home hand exercises improve hand function in patients with hand osteoarthritis: A randomized controlled trial. Arthritis Rheum 2002; 47(1):44-49.

7.190

111. Aletaha D, Smolen JS. Laboratory testing in rheumatoid arthritis patients taking disease- modifying antirheumatic drugs: Clinical evaluation and cost analysis. Arthritis Rheum 2002; 47(2):181-188.

7.190

112. Schett G, Smolen J, Zimmermann C, Hiesberger H, Hoefler E, Fournel S, Muller S,  Rubin RL and Steiner G. The autoimmune response to chromatin antigens in systemic lupus erythematosus: autoantibodies against hostone H1 are a highly specific marker for SLE associated with increased disease activity. Lupus 2002; (11): 704-715.

1.808

113. Wick M, Kainberger F, Smolen JS. Die radiologische Progession der rheumatoiden Arthritis bei frühzeitiger Basistherapie. Wien Klin Wochenschr 2002, Vol . 152, Suppl. Nr. 113

0.774

114. Grisar J, Bernecker PM, Aringer M, Redlich K, Sedlak M, Wolozcszuk W, Spitzauer S, Grampp S, Kainberger F, Ebner W, Smolen JS, Pietschmann P. Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002; 29(7):1430-1436.

2.674

115. Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 2002; 29(8):1631-1638.

2.674

116. Machold KP, Stamm TA, Eberl GJ, Nell VK, Dunky A, Uffmann M, Smolen JS. Very recent onset arthritis - clinical, laboratory and radiological findings during the first year of disease. J Rheumatol 2002; 29(11):2278-2287.

2.674

117. Aringer M, Feierl E, Steiner G, Stummvoll GH, Hofler E, Steiner CW, Radda I, Smolen JS,  Graninger WB. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 2002; 11(2):102-108.

1.808

118. Fureder W, Firbas U, Nichol JL, Pistillo J, Winkler S, Hiesberger H, Sperr WR, Smolen J,  Schett G. Serum thrombopoietin levels and anti-thrombopoietin antibodies in systemic lupus erythematosus. Lupus 2002; 11(4):221-226.

1.808

119. Steiner G, Shovman O, Skriner K, Gilburd B, Langevitz P, Miholits M, Hoet R, Levy Y, Zandman-Goddard G, Hoefler E, Smolen JS, Shoenfeld Y. Induction of anti-RA33 hnRNP autoantibodies and transient spread to U1- A snRNP complex of spliceosome by idiotypic manipulation with anti-RA33 antibody preparation in mice. Clin Exp Rheumatol 2002; 20(4):517-524.

1.919

120. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS,  Wagner EF, Schett G. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002; 110(10):1419-1427.

14.307

121. Fritsch R, Eselbock D, Skriner K, Jahn-Schmid B, Scheinecker C, Bohle B, Tohidast-Akrad M, Hayer S , Neumuller J, Pinol-Roma S, Smolen JS, Steiner G. Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J Immunol 2002; 169(2):1068-1076.

6.702

122. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology (Oxford) 2002; 41(12):1367-1374.

3.760

123. Kazemi-Shirazi L,  Gasche CH, Natter S, Gangl A, Smolen J, Spitzauer S , Valent P, Kraft D, Valenta R. IgA autoreactivity: a feature common to inflammatory bowel and connective tissue diseases. Clin Exp Immunol 2002; 128(1):102-109.

2.347

124. Tan EM, Smolen JS, McDougal JS, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, Reeves WH, Rothfield NF, Takasaki Y, Wiik A , Wilson M, Koziol JA. A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. J Rheumatol 2002; 29(1):68-74.

2.674

125. Galeazzi M, Sebastiani GD, Morozzi G, Carcassi C, Ferrara GB, Scorza R , Cervera R, De Ramon GE, Fernandez-Nebro A, Houssiau F, Jedryka-Goral A, Passiu G, Papasteriades C, Piette JC, Smolen J, Porciello G, Marcolongo R. HLA Class II DNA Typing in a Large Series of European Patients with Systemic Lupus Erythematosus: Correlations with Clinical and Autoantibody Subsets. Medicine (Baltimore) 2002; 81(3):169-178.

4.500

126. Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ, Fournel S, Fong D, Genovese MC, de Vegvar HE, Skriner K, Hirschberg DL, Morris RI, Muller S, Pruijn GJ, van Venrooij WJ, Smolen JS, Brown PO, Steinman L, Utz PJ. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 2002; 8(3):295-301.

30.550

127. Abarca-Costalago M, Abramovicz D, Allegri F, Annunziata P, Aydintug AO, Bacarelli MR, Bellisai F, Bernardino I, Biernat-Kaluza E, Blockmans D, Boki K, Bracci L, Campanella V, Camps MT, Carcassi C, Cattaneo R, Cauli A, Cercera R, Chwalinska-Sadowska H, Contu L, Cosyns JP, Danieli MG, D’Cruz D, Depresseux G, Direskeneli H, Domènech I, Espinosa G, Fernández-Nebro A, Ferrara GB, Font J, Frutos MA, Galeazzi M, García-Carrasco M, García-Iglesias MF, García-Tobaruela A, George J, Gil A, González-Santos P, Grana M, Gül A, Haga  HJ, de Haro-Liger M, Houssiau F, Hughes GRV, Ingelmo M, Jedryka-Góral A, Khamashta MA, Lavilla P, Levi Y, López-Dupla M, López-Soto A, Maldykowa H, Marcolongo R, Mathieu A, Morozzi G, Nicolopoulou N, Papasteriades C, Passiu G, Perelló I, Petera P, Petrovic R, Piette J-C, Pintado V, de Pita O, Popovic R, Pucci G, Puddu P, de Ramón E, Ramos-Casals M, Rodríguez-Andreu J, Ruiz-Irastorza G, Sánchez-Lora J, Sanna G, Scorza R, Sebastiani GD, Sherer Y, Shoenfeld Y, Simpatico A, Sinico RA, Smolen J, Tincani A, Tokgöz G, Urbano-Márquez A, Vasconcelos C, Vázquez JJ, Veronesi M, Vianna J, Vivancos J. Lessons from the „Euro-Lupus Cohort“. Ann Intern Med 2002; 153 (8): 530-536.

12.427

128. Steiner G, Smolen J. Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res 2002; 4 Suppl 2:S1-S5.

5.036

129. Smolen JS. Therapy of systemic lupus erythematosus: a look into the future. Arthritis Res 2002; 4 Suppl 3:S25-S30.

5.036

130. Graninger W, Smolen J. Treatment of Rheumatoid Arthritis by TNF-Blocking Agents. Int Arch Allergy Imm 2002; 127(1):10-14.

2.000

131. Simon LS, Smolen JS, Abramson SB, Appel G, Bombardier C, Brater DC, Breedveld FC, Brune K, Burmester GR, Crofford LJ,  Dougados M, DuBois RN, Fitzgerald GA, Frishman W, Garcia Rodriguez LA, Hochberg MC, Kalden JR, Laine L, Langman MJ, Prescott SM, van de Putte LB, Whelton A, White WB, Willaims GH. Controversies in COX-2 selective inhibition. J Rheumatol 2002; 29(7):1501-1510.

2.674

132. Dougados M, Smolen JS. Pharmacological management of early rheumatoid arthritis--does combination therapy improve outcomes? J Rheumatol Suppl 2002; 66:20-26.

2.674

133. Smolen JS. Rheumatic therapy. Trends Mol Med 2002; 8(8):408-409.

9.848

134. Steiner G, Smolen JS. Neue Antikörper in der Diagnostik der rheumatoiden Arthritis. Z Rheumatol 2002; 61(6):667-673.

0.531

135. Schett G, Redlich K, Hayer S, Zwerina J, Bolon B, Dunstan C, Görtz B, Schulz A, Bergmeister H, Kollias G, Steiner G, Smolen JS. Osteoprotegerin Protects From Generalized Bone Loss in Tumor Necrosis Factor-Transgenic Mice. Arthritis Rheum 2003;48 (7) : 2042-51.

7.190

136. Redlich K, Schett G, Steiner G, Hayer S, Wagner EF, Smolen JS. RA Therapy after TNF- and IL-1Blockade. Arthritis Rheum 2003;48:3308-3319.

7.190

137. Bobacz K, Gruber R, Soleiman A, Erlacher L, Smolen JS, Graninger WB. Expression of Bone Morphogenetic Protein 6 in Healthy and Osteoarthritic Human Articular Chondrocytes and Stimulation of Matrix Synthesis In Vitro. Arthritis Rheum 2003; 48(9): 2501-2508.

7.190

138. Stamm TA, Ploner A, Machold KP and Smolen J. Moberg Picking-Up Test in Patients With Inflammatory Joint Diseases: A Survey of Suitability in Comparison With Button Test and Measures of Disease Activity. Arthritis Rheum 2003; 15:49(5):626-32.

7.190

139. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, van Riel PL, Tugwell P. A Simplified Disease Activity Index for Rheumatoid Arthritis for  Use in Clinical Practice. Rheumatology 2003; 42:244-257

3.760

140. Köller MD, Kiener HP, Aringer M, Graninger WB, Meuer S, Samstag Y, Smolen JS. Functional and molecular aspects of transient T cell unresponsiveness: role of selective interleukin-2 deficiency. Clin Exp Immunol 2003; 132(2):225-231.

2.347

141. Aringer M, Hofmann SR, Frucht DM, Chen M, Centola M, Morinobu A, Visconti R, Kastner DL, Smolen JS and O’Shea JJ. Characterization and Analysis of the Proximal Janus Kinase 3 Promoter.  J Immunol 2003, 170(12): 6057-6064.

6.702

142. Fritzler MJ, Wiik A, Smolen JS, McDougal JS, Chan EKL, Gordon TP, Hardin JA, Kalden JR, Lahita RG, Maini RN, Reeves WH, Rothfield NF, Takasaki Y, Wilson M, Byrd MG,  Lloyd S, Koziol JA. A Critical Evaluation of Enzyme Immunoassay Kits for Detection of Antinuclear Autoantibodies of Defined Specificities. III. Comparative Performance Characteristics of Academic and manufacurer’s Laboratories.  J Rheumatol 2003; 30(11): 2374-2381.

2.674

143. Sebastiani GD, Galeazzi M, Tincani A, Scorza R, Mathieu A, Passiu G, Morozzi G, Piette JC, Cervera R, Houssiau F, Smolen J, Fernandez Nebro A, De Ramon E, Goral AJ, Papasteriades C, Ferrara GB, Carcassi C, Belllisai F, Marcolongo R. HLA-DPB 1 alleles association of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus 2003;12(7):560-3.

1.808

144. Stranzl T, Wolf J, Leeb BF, Smolen JS, Pirker R, Filipits M. Expression of folypolyglutanyl synthetase predicts poor response to methotrexate therapy in patients with rheumatoid arthritis. Clin Exp Rheumatol 2003;21:27-32.

2.347

145. Pincus T, Smolen JS. Early arthritis.Introduction. Clin Exp Rheumatol Suppl 2003;21:5 (31): 1

1.919

146. Machold KP, Nell VP, Stamm TA, Eberl G, Steiner G, Smolen JS. The Austrian Early Arthritis Registry. Clin Exp Rheumatol 2003 ;21:5 ( 31):113-7.

1.919

147. Smolen JS, Sokka T, Pincus T, Breedveld FC. A proposed treatment algorithm for rheumatoid arthritis: Aggressive therapy, methotrexate, and quantitative data. Clin Exp Rheumatol Suppl 2003; 21:5 (31):209-210.

1.919

148. Aletaha D, Kapral T, Smolen JS. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis. 2003; 62:482-6.

3.827

149. Furst DE, Breedveld  FC, Kalden JR, Smolen JS, Burmester GR, Dougadus M, Emery P, Gibofsky A, Kavanaugh AF, Keystone EC, Klareskog L, Russell AS, van de Putte LB, Weisman MH. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis. 2003;62(2):ii2-9.

3.827

150. Wick M, Peloschek P, Bogl K, Graninger W, Smolen JS, Kaiberger F. The “X-Ray RheumaCoach” software: a novel tool for enhancing the efficacy and accelerating radiological quantification in rheumatoid arthritis. Ann Rheum Dis. 2003; 62(6):579-82.

3.827

151. Aletaha D, Stamm T, Kapral T, Eberl G, Grisar J, Machold KP, Smolen JS. Survival and effectiveness of leflunomide compared wirth methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003; 62(10): 944-951.

3.827

152. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Bumester GR, Bijlsman JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 2004; 63 Suppl 2:ii2-iil2.

3.827

153. Aringer M, Smolen JS. SLE – Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther. 2003;5(4):172-7.

5.036

154. Schett G, Steiner C-W, Xu Q, Smolen JS and Steiner G. TNFα mediates susceptibility to heat-induced apoptosis by protein phosphatase-mediated inhibition of the HSF 1/hsp 70 stress response. Cell Death Differ 2003; 10(10):1126-1136.

7,008

155. Smolen JS, Steiner G. Therapeutic Strategies for Rheumatoid Arthritis. Nat Rev Drug Discov 2003;2:473-488.

17.732

156. Aletaha D, Smolen JS. Threats to Validity of Observational Studies on Disease-modifying Antirheumatic Drug Therapies for Rheumatoid Arthritis: New Aspects After The Fall of the Pyramid and the Rise of New Therapeutics. Curr Rheumatol Reports 2003, 5:409-412.

3.150

157. Smolen JS. Objectives and strategies for rheumatoid arthritis therapy: yesterday vs. today. Drugs Today (Barc.) 2003; 39: 3-8.

0.525

158. Machold KP, Smolen JS. Adalimumab – a new TNF-a antibody for treatment of inflammatory joint disease. Expert Opin.Biol.Ther. 2003;3(2): 351-360.

2.779

159. Schett G, Redlich K, Smolen JS. The role of osteoprotegerin in arthritis. Arthritis Res. Ther. 2003; 5(5): 239-45.

5.036

160. Bobacz K, Maier R, Fialka C, Ekhart H, Woloszczuk W, Geyer G, Erlacher L, Smolen J, Graninger WB. Is pro-matrix metalloproteinase-3 a marker for  posttraumatic cartilage degradation? Osteoarthr Cartilage 2003, 11(9): 665-672.

2.964

161. Redlich K, Görtz B, Hayer S, Zwerina J, Doerr N, Kostenuik P, Bergmeister H, Kollias G, Steiner G, Smolen JS, Schett G. Repair of local bone erosions and reversal of systemic bone loss upon combination therapy with anti-TNF, OPG and PTH in TNF-mediated arthritis. Am J Pathol  2004; 164(2):543-55.

6.946

162. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, Dunstan C, Kollias G, Steiner G, Smolen J, Schett G. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004; 50(1):277-90.

7.190

163. Redlich K, Görtz B, Hayer S, Zwerina J, Kollias G, Steiner G, Smolen JS, Schett G. Overexpression of tumor Necrosis Factor Causes Bilateral Sacroiliitis. Arthritis Rheum 2004; 50(3):1001-5.

7.190

164. Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G, Mayr A, Jocher J, Xu Q, Pietschmann P, Teitelbaum S, Smolen J, Willeit J. Soluble RANKL and Risk of Nontraumatic Fracture. JAMA, 2004; 291( 9):1108-1113.

21.455

165. Görtz B, Hayer S, Redlich K, Zwerina J, Tohidast-Akrad M, Türk B, Hartmann C, Kollias G, Steiner G, Smolen JS, Schett G. Arthritis induces lymphocytic bone marrow inflammation and endosteal bone formation. J Bone Miner Res 2004; 19(6):990-8.

6.225

166. Strand V, Cohen SB, Crawford B, Smolen JS, Scott DL. Patient-Reported Outcomes Better Discriminate Active Treatment From Placebo in Randomized Controlled Trials in Rheumatoid Arthritis. Rheumatology (Oxford) 2004; 43(5):640-7.

7.190

167. Nell VPK, Machold KP, Eberl G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with diseas modifying antirheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2004; 43(7):906-14.

3.760

168. Maini RN, Breedveld FC, Kalden  JR, Smolen JS, Furst D, Weisman MH, St.Clair EW, Keenan GF, Van der Heijde D, Marsters PA, Lipsky PE. Sustained Improvement Over Two Years in Physical Function, Structural Damage, and Signs and Symptoms Among Patients With Rheumatoid Arthritis Treated With Infliximab and Methotrexate.  Arthritis  Rheum 2004; 50(4): 1051-1065.

7.190

169. Breedveld FC, Emery P, Keystone E, Patel K, Marsters PA, Furst D, Kalden JR, St Clair EW, Weisman M, Smolen J, Lipsky PE and Maini R. Infliximab in active early rheumatoid Arthritis. Ann Rheum Dis 2004, 63:149-155.

3.827

170. Wick MC, Anderwald C, Weiss RJ, Imhof H, Kainberger F, Smolen JS. Radiological progression of joint damage in a longitudinal cohort of early DMARD-treated rheumatoid arthritis patients followed for 10 years. Scand J Rheumatol 2004; 33(3):162-6.

1.821

171. Köller MD, Zwölfer B, Steiner G, Smolen JS, Scheinecker C. Phenotypic and functional deficiencies of monocytederived dendritic cells in systemic lupus erythematosus (SLE) patients. Int Immunol 2004; 16(11):1595-604.

3.690

172. Smolen JS. Introduction: Practical Management of Rheumatoid Arthritis Patients Treated with Leflunomid . J Rheumatol Suppl 2004; 71:1-12.

2.674

173. Smolen JS, Emery P, Kalden JR, Van Riel PLCM, Dougados M, Strand CV, Breedveld F. The Efficacy of Leflunomide Monotherapy in Rheumatoid Arthritis: Towards the Goals of Disease Modifying Antirheumatic Drug Therapy. J Rheumatol Suppl 2004; 71:13-20.

2.674

174. Van Riel PL, Smolen JS, Emery P, Kalden JR, Dougados M, Strand CV, Breedveld FC. Leflunomide: a manageable safety profile. J Rheumatol Suppl 2004; 71:21-4.

2.674

175. Kalden JR, Smolen JS, Emery P, van Riel PL, Dougados M, Strand CV, Breedveld FC. Lefunomide in combination therapy. J Rheumatol Suppl. 2004; 71:25-30.

2.674

176. Rüger B, Giurea A, Wanivenhaus AH, Zehetgruber H, Hollemann D, Yanagida G, Groger M, Petzelbauer P, Smolen JS, Hoecker P, Fischer MB. Endothelial Precursor Cells in the Synovial Tissue of Patients With Rheumatoid Arthritis and Osteoarthritis. Arthritis  Rheum 2004; 50(7): 2157-2166.

7.190

177. Herrak P, Görtz B, Hayer S, Redlich K, Reiter E, Gasser J, Bergmeister H, Kollias G, Smolen JS, Schett G. Zoledronic Acid Protects Against Local and Systemic Bone Loss in Tumor Necrosis Factor – Mediated Arthritis. Arthritis  Rheum 2004; 50(7): 2327-2337.

7.190

178. Aringer M, Graninger WB,  Steiner G, Smolen JS. Safety and Efficacy of TNFα blockade in Systemic Lupus Erythematosus – an Open Label Study. Arthritis Rheum. 2004; 50(10):3161-3169.

7.190

179. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular Disease. Circulation 2004 ; 109(18):2175-2180.

11.164

180. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Bumester GR, Bijlsman JW, Dougados M, Emery P, Keystone EC, Klareskog L, Mease PJ. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 2004; 63 Suppl 2:ii2-iil2.

3.827

181. Bobacz K, Erlacher L, Smolen J, Soleiman A, Graninger WB. Chondrocyte number and proteoglycan synthesis in the aging and osteoarthritic human articular cartilage. Ann Rheum Dis 2004; 63:1618-1622.

3.827

182. Köller MD, Templ E, Riedl M, Clodi M, Wagner O, Smolen JS, Luger A. Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus. Ann Rheum Dis 2004; 63:1677-1680.

3.827

183. Smolen JS. Combating the burden of musculoskeletal conditions. Ann Rheum Dis 2004; 63(4):329.

3.827

184. Smolen JS, Aletaha D. Patients with rheumatoid arthritis in clinical care – The challenge of following process, damage, and function.Ann Rheum Dis 2004; 63(5):221-225.

3.827

185. Stummvoll GH, Aringer M, Grisar J, Steiner CW, Smolen JS, Knobler R, Graninger WB.  Increased transendothelial migration of scleroderma lymphocytes. Ann Rheum Dis 2004; 63(5):569-574.

3.827

186. Stamm TA, Aletaha D, Machold KP, Smolen JS. Disease Activity Measurement in Patients with Rheumatoid Arthritis.  J Rheumatol 2004; 2(4):114-9.

2.674

187. Van der Heijde D, Kalden J, Scott D, Smolen J, Strand V. Long-term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years: concise report. Ann Rheum Dis 2004; 63(6):737-9.

3.827

188. Dougados M, Betteridge N, Burmester GR, Euller-Ziegler L, Guillemin f, Hirvonen J, Lloyd J, Ozen S, da Silva JAP, Emery P, Kalden J, Kvien T, Matucci-Cerinic M, Smolen J. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004; 63(9):1172-6.

3.827

189. Aletaha D, Eberl G, Nell VP, Machold KP, Smolen JS. Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. Ann Rheum Dis 2004; 63(10):1269-75.

3.827

190. Grisar J, Aringer M, Köller MD, Stummvoll GH, Eselböck D, Zwölfer B, Steiner CW, Zierhut B, Pietschmann P, Smolen JS. Leflunomide Inhibits Transendothealial Migration of Peripheral Blood Mononuclear Cells. Ann Rheum Dis 2004; 63(12):1632-7.

3.827

191. Liang  MH et al. The American College of Rheumatology Response Criteria for Systemic Lupus Erythematosus Clinical Trials. Measures of Overall Disease Activity. Arthritis Rheum 2004; 50(11):3418-3426.

7.190

192. St.Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial. Arthritis Rheum 2004; 50(11):3432-43.

7.190

193. Stamm TA, Cieza A, Machold KP, Smolen JS, Stucki G. Content comparison of occupation – based instruments in adult rheumatology and musculoskeletal rehabilitation based on the International Classification of Functioning, Disability and Health. Arthritis Rheum 2004; 51(6):917-924.

7.190

194. Stummvoll GH, Aringer M, Jansen M, Smolen JS, Derfler K, Graninger WB. Immunoadsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy. Wien Klin Wochenschr 2004; 116(21-22):716-724.

0.774

195. Schett G, Kiechl S, Bonora E, Redlich K, Woloszczuk W, Oberhollenzer F, Jocher J, Dorizzi R, Muggeo M, Smolen J, Willeit J. Serum leptin level and the risk of nontraumatic fracture. Am J Med 2004; 117(12):952-6.

4.403

196. Smolen JS, Hayer S, Schett G, Redlich K, Aringer M, Kollias G, Wagner E, Steiner G. Autoimmunity and rheumatoid arthritis. Autoimmun Rev 2004; 3 (Suppl 1):23

0

197. Stamm T, Wright J, Machold K, Sadlo G, Smolen J. Occupational balance of women with rheumatoid arthritis: A qualitative study. Musculoskeletal Care 2004; 2(2): 101-112.

0

198. Aringer M, Smolen JS. Tumor necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 2004; 13:344-347.

1.808

199. Kirsch BM, Zeyda M, Stuhlmeier K, Grisar J, Smolen JS, Watschinger B, Stulnig TM, Hörl WH, Zlabinger GJ, Säemann MD. The active metabolite of leflunomide,  A77 1726, interferes with dendritic cell function. Arthritis Res Ther 2005; 7:R694-R703.

5.036

200. Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, Tugwell P, Crawford B, Leflunomide Rheumatoid Arthritis. Investigators Groups. Physical function and health related quality of life: analysis of 2 year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005; 32(4):590-601.

2.674

201. Wolf J, Stranzl T, Filipits M, Pohl G, Pirker R, Leeb BF, Smolen JS. Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64(4):564-8.

3.827

202. Smolen JS. In the middle of the decade. Ann Rheum Dis 2005;64(6):797.

3.827

203. Grisar J, Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D, Weigel G, Schwarzinger I, Wolocszuk W, Steiner G, Smolen JS. Depletion of Endothelial Progenitor Cells in the Peripheral Blood of Patients with Rheumatoid Arthritis. Circulation 2005; 111:204-211.

11.164

204. Köller M, Hayer S, Redlich K, Ricci R, David JP, Steiner G, Smolen JS, Wagner EF, Schett G. JNF 1 is not essential for TNF-mediated joint disease. Arthritis Res Ther 2005; 7:166-73.

5.036

205. Hayer S, Steiner G, Görtz B, Reiter B, Tohidast-Akrad M, Amling M, Hoffmann O, Redlich K, Zwerina J, Skriner K, Hilberg F, Wagner EF, Smolen JS, Schett G. CD44 is a determinant of inflammatory bone loss. J Exp Med 2005; 201(6):903-14.

15.302

206. Aletaha D, Nell VPK, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther  2005; 7(4):R796-R806.

5.036

207. Smolen JS, Han C, Bala M, Maini R, Kalden J, Van der Heijde D, Breedveld  FC, Furst DE, Lipsky PE. Evidence of Radiographic Benefit of Treatment with Infliximab plus Methotrexate in Rheumatoid Arthritis Patients who had no Clinical Improvement. Arthritis Rheum 2005; 52(4):1020-30.

7.190

208. Antoni CE, Kavanaugh A, Kirkham b, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritic: results from the infliximab multinational psoriatic arthritic controlled trial (IMPACT). Arthritis Rheum 2005; 52(4):1227-36

7.190

209. Smolen JS, Aletaha D, Machold KP. Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005; 19(1):163-77.

1.356

210. Aringer M, Smolen JS. Cytokine expression in lupus kidneys. Lupus 2005;14(1):13-18.

1.808

211. Smolen JS, Steiner G, Aringer M. Anti-cytokine therapy in systemic lupus erythematosus. Lupus 2005; 14:189-191.

1.808

212. Smolen JS. The science of rheumatoid arthritis: a prelude. Arthritis Res Ther 2005; 7 Suppl 2:S1-S3.

5,036

213. Aringer M, Steiner G, Smolen JS. Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am. 2005; 31(3):411-20.

2,776

214. Schett G, Herrak P, Graninger W, Smolen JS, Aringer M. Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature. J Clin Microbiol 2005; 43(5): 2537-41.

3.489

215. Stamm TA, Cieza A, Coenen M, Machold KP, Nell VP, Smolen JS, Stucki G. Validating the International  Classification of Functioning, Disability and Health Comprehensive Care Set for Rheumatoid Arthritis from the patient perspective: A qualitative study. Arthritis Rheum 2005; 53(3):431-439.

7.190

216. Stummvoll GH, Aringer M, Smolen JS, Schmaldienst S, Jimenez-Boj E, Hörl WH, Graninger WB, Derfler K. IgG immunoadsorption (IAS) reduces SLE activity and proteinuria – a long term observational study. Ann Rheum Dis 2005; 64(7):1015-21.

       3.827

217. Jimenez-Boj E, Redlich K, Türk B, Hanslik-Schnabel B, Wanivenhaus A, Chott A, Smolen JS, Schett G. Interaction between Synovial Inflammatory Tissue and Bone Marrow in Rheumatoid Arthritis. J Immunol 2005; 175(4):2579-88.

6.702

218. Kalden JR, Antoni C, Alvaro-Gracia JM, Combe B, Emery P, Kremer JM, Strand CV, Van Riel P, Smolen JS. Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. J Rheumatol 2005; 32(8):1620-31.

2.674

219. Görtz B, Türk B, Hayer S, Redlich K, Zwerina J, Smolen JS, Schett G. TNF activates the mitogen activated protein kinases p38 and ERK in the synovial membrane in vivo. Arthritis Res Ther 2005; 7:R1140-R1147

5.036

220. Bobacz K, Ullrich R, Erlacher L, Smolen JS, Graninger WB. Stimulatory effects of district members of the Bone morphogenetic protein family on ligament fibroblasts. Ann Rheum Dis 2005.(in press)

3.827

221. Nell VPK, Machold KP, Stamm TA, Eberl G, Hueber W, Heinzl H, Uffmann M, Hoefler E, Smolen JS, Steiner G. Autoantibody Profiling as Early Diagnostic and Prognostic Tool For Rheumatoid Arthritis. Ann Rheum Dis 2005 May 5, (e-pub ahead of printing).

       3.827

222. Stamm TA, Cieza A, Machold KP, Smolen JS, Stucki G. An Exploration of the Link of Conceptual Occupational Therapy Models to the International Classification of Functional, Disability and Health (ICF). The Austrialian Occupational Therapy Journal 2005; (in press)

0

223. Zwerina J, Tzima S, Hayer S, Redlich K, Hoffmann O, Hanslik-Schnabl B, Smolen J, Kollias G, Schett G. Heme Oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption. Faseb J (in press)

7.172

224. Aletaha D, Smolen JS, The Definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin North Am 2005 ( in press)

2.776

225. Smolen JS, Aletaha D, Keystone E. Superior efficacy of Combination Therapy for rheumatoid arthritis: Fact or Fiction? Arthritis Rheum (in press)

7.190

226. Aletaha D, Smolen JS. Disease Activity Indices for Rheumatoid Arthritis – A Review of the SDAI and CDAI. Clin Exp Rheumatol (in press).

1.919

227. Aletaha D, Breedveld FC, Smolen JS. Do we need new classification criteria for RA? Yes, we do. Arthritis Rheum (in press).

7.190

228. Aletaha D, Ward MM, Machold KP, Nell VPK, Stamm T, Smolen JS. Remission and Active Disease in Rheumatoid Arthritis: Defining Criteria for Disease Activity States. Arthritis Rheum (in press).

7.190

229. Aletaha D, Smolen JS. The ACR-N debate: going back into the middle of the tunnel? Arthritis Rheum (letter,in press).

7.190

230. Aletaha D, Smolen JS. How can we predict a treatment response in rheumatoid arthritis? Nature Pract Rheumatol 2005 (in press).

231. Smolen JS, Maini RN, Han C, Baker D, Lipsky P. The dichotomy of inflammation and destruction in RA. Arthritis Rheum 2005 (in press).

7.190

232. Hayer S, Tohidast-Akrad M, Haralambous S, Jahn-Schmid B, Skriner K, Trembleau S, Dumortier H, Pinol-Roma S, Redlich K, Schett G, Müller S, Kollias G, Smolen J, Steiner G. Aberrant expression of the autoantigen hnRNP-A2/B1 (RA33) and spontaneous formation of rheumatoid arthritis associated anti-RA33 autoantibodies in TNFα transgenic mice. J Immunol 2005 (in rev)

6.702

233. Jimenez-Boj E, Kedersha N, Tohidast-Akrad M, Karlhofer FM, Stummvoll G, Zimmermann C, Ulrich W, Guiducci S, Hoefler E, Schett G, Matucci-Cerinic M, Anderson P, Smolen JS, Steiner G. Autoantibodies to the translational supressors TIA-1 and TIAR occur frequently in patients with systemic lupus erythematosus and scleroderma and correlate with clinical features. Arthritis Rheum 2005 (in rev)

7.190

234. Stummvoll GH, Fritsch R, Meyer B, Aringer M, Smolen JS, Steiner G. Characterization of T cell responses to histone H1 and core histones in patients with systemic lupus erythematosus. Arthritis Rheum 2005(in rev)

7.190

235. Zwerina J, Hayer S, Redlich K, Bobacz K, Kollias G, Smolen JS, Schett G. Activation of p38MAPK is a key step in TNF-mediated inflammatory bone destruction . Arthritis Res Ther 2005 (in rev).

5.036

236. Zwerina J, Türk B, Redlich K, Smolen JS, Schett G. Dysbalance of local bone metabolism in inflammatory arthritis and its reversal upon TNF blockade: direct analysis of bone turnover in murine arthritis. Arthritis Res Ther 2005 (in rev)

5.036

Total score

690.427